How long will markets sustain high priced orphan drugs? 7 February 2013 / By andre / Clinical Trials, Drug Discovery, Manufacturing, Market Access, Orphan Drugs, Partnering & Investment, Regulation and Government / 0 comments
The Big Orphan Drug Debate – Share your opinions and make a difference 5 February 2013 / By neild / Clinical Trials, Market Access, Orphan Drugs, Partnering & Investment, Regulation and Government / 0 comments
PHARMA MEXICO- new opportunity for locals and multinational entrants 2 February 2013 / By sarat / Manufacturing, Market Access, Orphan Drugs, Partnering & Investment, Regulation and Government / 0 comments
The impact of comparability on orphan drug development 31 January 2013 / By andre / Clinical Trials, Drug Discovery, Drug Safety, Manufacturing, Market Access, Orphan Drugs, Regulation and Government / 0 comments
Download: eBook ‘Top tips for successful commercialisation and scalable manufacture of cell therapies’ 8 January 2013 / By Matt Turner / Manufacturing, Partnering & Investment, Regenerative Medicine, Regulation and Government / 1 comment
Why orphan drugs are a key part of pharma’s future? 30 November 2012 / By andre / Clinical Trials, Drug Discovery, Manufacturing, Market Access, Orphan Drugs, Partnering & Investment, Regulation and Government / 0 comments
Jihoon Baang: How to Navigate Regulatory Compliances and Clinical Trials in South Korea 27 November 2012 / By jolene / Clinical Trials, Regulation and Government / 0 comments
Europe’s reaction to CAVOMP’s harmonization in the orphan drugs space 15 November 2012 / By andre / Drug Discovery, Orphan Drugs, Partnering & Investment, Regulation and Government / 0 comments
Quintiles embarks on first global trial with participation from Indonesian patients 1 November 2012 / By jolene / Clinical Trials, Partnering & Investment, Regulation and Government / 0 comments
Is drug repositioning surpassing new brands discovery and development? 25 October 2012 / By andre / Clinical Trials, Drug Discovery, Drug Safety, Manufacturing, Orphan Drugs, Partnering & Investment, Regulation and Government, Reports / 0 comments
